SEC Form 4 · accession 0001140361-17-012643
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel K Spiegelman
Officer — EVP, Chief Financial Officer
Period of report
Mar 15, 2017
Accepted (ET)
Mar 17, 2017 · 6:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 15, 2017 | F | 4,301 | $92.50 | D | 16,460 | D | |
| Common StockF1,F2 | Mar 16, 2017 | S | 1,989 | $91.96 | D | 14,471 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Trade made pursuant to a 10b5-1 plan executed on November 16, 2016.
- F2All shares were sold at the same price.